IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients with Clinical T1-2N0 ER+ Her2- Breast Cancer with Ultrasound Detected Nodal Metastases
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Radiation, Procedure
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 45
Healthy Volunteers: f
View:
• Women age ≥ 45
• Clinical T1-2N0 ER+ invasive breast cancer
• US detected biopsy proven axillary nodal disease
• Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Locations
United States
California
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
RECRUITING
Los Angeles
CS Cancer at Huntington Cancer Center
RECRUITING
Pasadena
CS Cancer at Valley Oncology Medical Group
RECRUITING
Tarzana
Contact Information
Primary
Clinical Trial Navigator
cancer.trial.info@cshs.org
3104232133
Time Frame
Start Date: 2024-04-07
Estimated Completion Date: 2031-04
Participants
Target number of participants: 45
Treatments
Experimental: Single Arm
Related Therapeutic Areas
Sponsors
Leads: Alice Chung